| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041885464 |
| P356 | DOI | 10.1007/S12094-012-0856-5 |
| P698 | PubMed publication ID | 22855150 |
| P50 | author | Rocío García-Carbonero | Q51093358 |
| Santiago Ramon y Cajal | Q55188014 | ||
| P2093 | author name string | Eva Musulén | |
| Samuel Navarro | |||
| Pilar García-Alfonso | |||
| Ramón Salazar | |||
| Jesús García-Foncillas | |||
| Artemio Payá | |||
| Pedro Pérez-Segura | |||
| Spanish Society of Medical Oncology (SEOM) | |||
| Spanish Society of Pathology (SEAP) | |||
| P2860 | cites work | Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability | Q24618618 |
| PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis | Q26992267 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab | Q27851587 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis | Q28269226 | ||
| Systematic review of microsatellite instability and colorectal cancer prognosis | Q28303189 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer | Q56601042 | ||
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study | Q57152185 | ||
| Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome | Q57260018 | ||
| SMAD4 as a Prognostic Marker in Colorectal Cancer | Q57567752 | ||
| Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients | Q58109622 | ||
| PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients | Q58813317 | ||
| Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis | Q60035708 | ||
| Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue | Q60277142 | ||
| Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer | Q60502811 | ||
| Hereditary colorectal cancer | Q73088287 | ||
| American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing | Q74139327 | ||
| Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system | Q74555369 | ||
| Stage II colon cancer prognosis prediction by tumor gene expression profiling | Q80244020 | ||
| Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab | Q80704669 | ||
| Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma | Q82651211 | ||
| Colorectal Cancer OncoGuia: surgical pathology report guidelines | Q83192646 | ||
| Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis | Q83978360 | ||
| Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle | Q84150581 | ||
| Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status | Q33620091 | ||
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 | ||
| Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum | Q33983862 | ||
| Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin | Q34131764 | ||
| Molecular staging for survival prediction of colorectal cancer patients | Q34420506 | ||
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial | Q34614245 | ||
| KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. | Q34727184 | ||
| DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. | Q35031411 | ||
| KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications | Q35069989 | ||
| PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients | Q36611365 | ||
| EGFR and colon cancer: a clinical view. | Q37061584 | ||
| Current overview of the role of Akt in cancer studies via applied immunohistochemistry | Q37104138 | ||
| PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer | Q37137091 | ||
| KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications | Q37668163 | ||
| PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab | Q38584695 | ||
| Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. | Q38934630 | ||
| A robust immunohistochemical assay for detecting PTEN expression in human tumors | Q39646962 | ||
| PTEN status in advanced colorectal cancer treated with cetuximab. | Q42927164 | ||
| KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial | Q43250046 | ||
| EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. | Q43256499 | ||
| The DCC protein and prognosis in colorectal cancer | Q44846916 | ||
| Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | Q46465639 | ||
| Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer | Q46742453 | ||
| Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH. | Q47911951 | ||
| Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. | Q51502354 | ||
| Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. | Q51597657 | ||
| Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. | Q51597972 | ||
| Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. | Q51976500 | ||
| Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. | Q52846071 | ||
| Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. | Q53272007 | ||
| Clinical significance of tumor suppressor PTEN in colorectal carcinoma. | Q53291653 | ||
| Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. | Q53370638 | ||
| Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. | Q54576044 | ||
| New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. | Q55033068 | ||
| P433 | issue | 10 | |
| P921 | main subject | biomarker | Q864574 |
| medical oncology | Q6050805 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 726-739 | |
| P577 | publication date | 2012-07-27 | |
| P1433 | published in | Clinical and Translational Oncology | Q15754324 |
| P1476 | title | Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) | |
| P478 | volume | 14 |
| Q42335970 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines |
| Q45283566 | From single protein to colorectal cancer genome landscape and network biology-based biomarkers |
| Q44077280 | Gene expression 'signature' limitations and genome architecture-based perspectives for robust cancer biomarkers |
| Q35742491 | Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. |
| Q34876437 | KRAS mutation analysis by PCR: a comparison of two methods |
| Q38136134 | KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. |
| Q43531971 | RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group |
| Q26827212 | Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF |
| Q38265382 | Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology |
Search more.